Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
5.81
+0.18 (3.20%)
At close: Apr 28, 2026, 4:00 PM EDT
5.92
+0.11 (1.89%)
After-hours: Apr 28, 2026, 6:06 PM EDT
Lexeo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | - | - | 0.65 | 1.66 | |
| Revenue Growth (YoY) | - | - | - | -60.53% | 219.59% | |
| Cost of Revenue | 63.8 | 74.09 | 53.13 | 49.16 | 45.12 | |
| Gross Profit | -63.8 | -74.09 | -53.13 | -48.51 | -43.46 | |
| Selling, General & Admin | 45.46 | 31.68 | 15.38 | 12 | 7.17 | |
| Operating Expenses | 45.46 | 31.68 | 15.38 | 12 | 7.17 | |
| Operating Income | -109.26 | -105.77 | -68.51 | -60.51 | -50.64 | |
| Interest Expense | -0.1 | -0.14 | -0.21 | -0.09 | - | |
| Interest & Investment Income | 6.13 | 7.56 | 2.87 | 1.33 | 0.02 | |
| Other Non Operating Income (Expenses) | -0.02 | -0.01 | -0.54 | -0 | - | |
| EBT Excluding Unusual Items | -103.24 | -98.36 | -66.39 | -59.28 | -50.62 | |
| Gain (Loss) on Sale of Investments | 3.28 | 0.02 | - | - | - | |
| Pretax Income | -99.96 | -98.33 | -66.39 | -59.28 | -50.62 | |
| Net Income | -99.96 | -98.33 | -66.39 | -59.28 | -50.62 | |
| Net Income to Common | -99.96 | -98.33 | -66.39 | -59.28 | -50.62 | |
| Shares Outstanding (Basic) | 54 | 32 | 5 | 2 | 2 | |
| Shares Outstanding (Diluted) | 54 | 32 | 5 | 2 | 2 | |
| Shares Change (YoY) | 68.76% | 493.67% | 228.42% | 5.00% | 7.72% | |
| EPS (Basic) | -1.86 | -3.09 | -12.40 | -36.36 | -32.60 | |
| EPS (Diluted) | -1.86 | -3.09 | -12.40 | -36.36 | -32.60 | |
| Free Cash Flow | -98.96 | -81.63 | -59.61 | -55.23 | -44.37 | |
| Free Cash Flow Per Share | -1.84 | -2.57 | -11.13 | -33.88 | -28.58 | |
| Operating Margin | - | - | - | -9252.14% | -3055.94% | |
| Profit Margin | - | - | - | -9063.76% | -3055.04% | |
| Free Cash Flow Margin | - | - | - | -8445.26% | -2677.73% | |
| EBITDA | -108.67 | -105.14 | -67.94 | -60.24 | -50.62 | |
| D&A For EBITDA | 0.59 | 0.63 | 0.58 | 0.27 | 0.01 | |
| EBIT | -109.26 | -105.77 | -68.51 | -60.51 | -50.64 | |
| Revenue as Reported | - | - | - | 0.65 | 1.66 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.